Page 288 - IJB-9-1
P. 288

International Journal of Bioprinting                                               3D-Printed scaffolds



            A                                B                               C
















            Figure 4. XRD of poly(ε-caprolactone) (PCL)/β-tricalcium phosphate (TCP) (A), poly(trimethyl carbonate) (PTMC)/TCP (B), and PTMC/PCL/TCP
            (C) scaffolds with different TCP content.

            A                                B                                C















            Figure 5. Compressive modulus of poly(ε-caprolactone) (PCL)/β-tricalcium phosphate (TCP) (A), poly(trimethyl carbonate) (PTMC)/TCP (B), and
            PTMC/PCL/TCP (C) scaffolds with different TCP content.

            Table 1. Compressive property of PCL/TCP, PTMC/TCP, and   3.5. DOX release property
            PTMC/PCL/TCP scaffolds
                                                               All scaffolds demonstrated substantial release rates and
             Scaffolds            Compressive   Fσ=50% (N)     steady drug controlled release properties during 130 days of
                                 modulus (MPa)                 measurement (Figure 8). PTMC/TCP scaffolds with different
            PCL                     111.8         1157.7       TCP content showed similar DOX release rates. Compared
            PCL/5%TCP               207.0         2065.8       with PTMC/TCP scaffolds, PTMC/PCL/TCP scaffolds
            PCL/10%TCP              248.2         2223.0       displayed faster DOX release rates, presumably due to the
            PCL/15%TCP              274.1         2423.8       large pores of scaffolds and high drug diffusion coefficient.
            PCL/20%TCP              290.9         2570.1       PCL/TCP scaffolds displayed obviously slower release rates
            PCL/25%TCP              298.8         2682.9       because of its low hydrophilicity, slow degradation rate, and
            PTMC                     1.5           81.4        low drug diffusion coefficient. Meanwhile, the DOX release
            PTMC/5%TCP               5.6          312.8        rates of scaffolds increased with the increased of TCP content.
            PTMC/10%TCP              7.1          371.5        PTMC/PCL/25%TCP and PTMC/25%TCP displayed 18.1%
            PTMC/15%TCP              8.3          241.3        and 14.1% of cumulative DOX release, respectively, which
            PTMC/20%TCP              10.1         303.1        were higher than PCL/TCP (3.1%). Thus, TCP improved
            PTMC/25%TCP              13.5         470.6        the hydrophilicity, drug diffusion coefficients, and DOX
            PTMC/PCL                 76.5         1099.6       release rates of scaffolds. These results are consistent with
            PTMC/PCL/5%TCP           86.2         1277.1       the micrographs structures of PCL/TCP, PTMC/TCP, and
            PTMC/PCL/10%TCP          93.6         1299.2       PTMC/PCL/TCP scaffolds in this study.
            PTMC/PCL/15%TCP         113.0         1348.3
            PTMC/PCL/20%TCP         129.8         1468.6       3.6. In vitro biocompatibility assay
            PTMC/PCL/25%TCP         154.8         1552.4
            PCL: Poly(ε‑caprolactone); TCP: β‑tricalcium phosphate; PTMC: Poly (trimethyl   Porous 3D-printed PCL/TCP, PTMC/TCP, and PTMC/
            carbonate)                                         PCL/TCP scaffolds can provide a large surface area, which

            Volume 9 Issue 1 (2023)                        280                      https://doi.org/10.18063/ijb.v9i1.641
   283   284   285   286   287   288   289   290   291   292   293